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Countries such as Sweden that have a low prevalence 
of methicillin-resistant Staphylococcus aureus (MRSA) of-
fer the opportunity to discern and study transmission of im-
ported cases of MRSA. We analyzed 444 imported cases of 
MRSA acquisition reported in Sweden during 2000–2003. 
Risk for MRSA in returning travelers ranged from 0.1 (95% 
conﬁ  dence interval [CI] 0.01–0.4) per 1 million travelers to 
Nordic countries to 59.4 (95% CI 44.5–79.3) per 1 million 
travelers to North Africa and the Middle East. Most imported 
cases (246, 55%) were healthcare acquired, but regions with 
the highest risk for MRSA in travelers showed a correlation 
with community acquisition (r = 0.81, p = 0.001). Charac-
teristic differences in MRSA strains acquired were depen-
dent on the region from which they originated and whether 
they were community or healthcare acquired. Knowledge of 
differences in transmission of MRSA may improve control 
measures against imported cases.
G
lobal transmission of methicillin-resistant Staphylo-
coccus aureus (MRSA) has been the subject of many 
studies. Conclusions have commonly been drawn from the 
occurrence of identical or similar strains in different coun-
tries or regions (1–6). Studies of individual MRSA cases 
linked to international travel have often been in the form 
of case reports, case series, or other descriptive reports 
(7–11). Only a few small analytical or population-based 
studies have been published (12–14). In countries with a 
high prevalence of MRSA, imported cases of MRSA are 
not easily distinguished from the domestic background 
prevalence. Thus, low prevalence countries, such as Swe-
den, offer a better opportunity to discern and study import-
ed cases of MRSA.
The primary purpose of our study was to use validat-
ed data from the surveillance system in Sweden to analyze 
the risk for MRSA among Swedish residents traveling 
abroad, internationally adopted children, and immigrants. 
A secondary purpose was to determine whether different 
types of MRSA were acquired in different countries or 
regions.
Materials and Methods
Data on MRSA Cases in the Statutory Swedish 
Communicable Disease Notiﬁ  cation System
The study was reviewed and approved by the Re-
gional Ethics Approval Board in Stockholm (Protocol 
2005/4:10). MRSA cases (infections as well as carriage) 
are notiﬁ  ed in parallel to the Swedish Institute for Infec-
tious Disease Control (SMI) by the doctor caring for the 
patient and by the bacteriological laboratory having iso-
lated the MRSA strain, using a unique personal identiﬁ  ca-
tion number issued to all Swedish residents and used in 
all contacts with the health care system. At SMI, a case 
record is created after the arrival of the ﬁ  rst notiﬁ  cation. 
Any subsequent notiﬁ  cations are merged with the initial 
case record. After completion of the epidemiologic inves-
tigation and contact tracing around each MRSA case, the 
epidemiologic notiﬁ  cation form data are validated by SMI 
with input from MRSA contact persons, who are public 
health representatives involved in control efforts locally 
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in the respective counties (15). The validated variables 
used in the study were age, sex, transmission setting 
(healthcare acquired [HA] or community acquired [CA]), 
country of acquisition, and purpose of travel (leisure or 
work related) (16). If a person infected with MRSA had 
been abroad <6 months before MRSA was diagnosed and 
either had a strain that was present in other persons from 
that region or had one that was previously unknown in 
Sweden and no likely source of MRSA in Sweden was 
found in the epidemiologic investigation, that person was 
considered to have acquired MRSA abroad. If there was 
a reasonable possibility that MRSA could have been ac-
quired either domestically or abroad, country of acquisi-
tion was considered unknown. If the person infected with 
MRSA had been admitted to or had worked in a health-
care setting during his or her stay abroad, he or she was 
considered to have a case of HA MRSA. Information in 
the study database on whether a person had MRSA dis-
ease or MRSA carriage was based on clinical case data 
from the physician caring for the patient. 
For additional analysis, the reported cases of MRSA 
were divided into the following categories: residents of 
Sweden traveling abroad for recreational purposes, resi-
dents of Sweden traveling abroad because of work or stud-
ies, foreign residents traveling to Sweden for a temporary 
visit, immigrants, internationally adopted children, or 
Swedish citizens returning home after having lived abroad 
for >1 year. The risk for MRSA in travelers, immigrants, 
and adopted children was also evaluated by including and 
excluding reported cases found through public health-ini-
tiated case-ﬁ  nding activities and secondary cases in trans-
mission chains.
Swedish Tourist and Travel Database
Travel data from the commercial Swedish Tourist 
and Travel Database (TDB) were used as a denomina-
tor when analyzing the risk for being reported as having 
MRSA in travelers from Sweden. The TDB is based on 
monthly interviews with 2,000 randomly selected resi-
dents of Sweden. We used the TDB variables age group, 
sex, purpose of travel (leisure or work), main destination, 
and time of travel. TDB for 2000–2003 and interviews of 
9,213 persons with a history of travel abroad were used. 
Information in the TDB was weighted and extrapolated to 
estimate the total number of travelers from Sweden and to 
derive a total of 45,855,000 travel episodes (17). Actual 
interviewees were used as controls in an adjusted model 
that estimated the odds ratio (OR) of having MRSA, and 
extrapolated estimates were used to calculate risks per 
1,000,000 travelers. Because only persons <75 years of 
age were sampled for interviews for the TDB, 34 cases of 
MRSA in persons >74 years of age were excluded from 
the TDB analyses.
Data on Immigration and International Adoptions
Denominator data on the yearly number of immigrants 
to Sweden were obtained from Statistics Sweden (18). 
Included in the immigration ﬁ  gures were persons who re-
ceived a residence permit because of family ties, European 
Economic Area convention, and labor permits; visiting stu-
dents; and asylum seekers per country of citizenship. Data 
on the yearly number of international adoptions per country 
were obtained from the Swedish Intercountry Adoptions 
Authority (19).
Epidemiologic Typing of MRSA Isolates
Isolates from all persons with new cases of MRSA 
were sent to SMI, where laboratory diagnosis of MRSA 
was conﬁ  rmed by using PCR for the mecA and the nuc 
genes (20). Epidemiologic typing of all isolates was per-
formed by using pulsed-ﬁ  eld gel electrophoresis (PFGE) 
according to the protocol of Murchan et al. (21). On the 
basis of PFGE results, representative isolates were selected 
for multilocus sequence typing (MLST) (22), and sequence 
types (STs) of isolates were determined by using the MLST 
database (www.mlst.net).
Statistical Analysis
Stata 8.2 software (StataCorp LP, College Station, TX, 
USA) was used for all statistical analyses, and a 95% lev-
el of signiﬁ  cance was applied. Sex, age group, purpose of 
travel, and destination were used as explanatory variables 
in multivariable analysis of travelers with a diagnosis of 
MRSA and its reporting as an outcome. Generalized esti-
mating equations with independent correlation and robust 
standard errors were used to enable clustering of data in the 
adjusted model that included all travelers <75 years of age.
Results
During 2000–2003, a total of 1,733 cases of MRSA 
were reported in Sweden, 444 of which were considered 
to have been acquired abroad. Among these imported 
cases, 292 (65.8%) were in residents of Sweden who trav-
eled abroad; 31 (7.0%) had traveled for work reasons or 
studies. Fifty-six (12.6%) of the cases were in newly ar-
rived immigrants to Sweden, 40 (9.0%) in internationally 
adopted children from non-Nordic countries, 30 (6.8%) in 
foreign residents visiting Sweden, 20 (4.5%) in citizens of 
Sweden returning home after having lived abroad for >1 
year, and 6 (1.4%) in persons who could not be grouped. 
Of the imported MRSA cases, 246 (55.4%) were HA and 
146 (32.9%) were CA; 190 (42.8%) were in persons with 
MRSA disease.
MRSA in Travelers Returning to Sweden
Of the 292 residents of Sweden who traveled abroad, 
267 met the age criteria and were included in this analysis. 
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Most persons with MRSA had traveled to Thailand (n = 
33), the United Kingdom (n = 24), Greece (n = 22), the 
former Yugoslavia (n = 20), Lebanon (n = 16), the United 
States (n = 14), Cyprus (n = 12), Spain (n = 12), Turkey (n 
= 9), and Syria (n = 8). The overall risk for being reported 
as having MRSA was 5.8 cases/1,000,000 travelers (95% 
conﬁ  dence interval [CI] 5.2–6.6). The crude risk for travel-
ers to speciﬁ  c regions ranged from 0.1 (95% CI 0.01–0. 4) 
per 1,000,000 travelers to Nordic countries to 59.4 (95% 
CI 44.5–79.3) per 1,000,000 travelers to North Africa and 
the Middle East (Table 1). Rank in risk for MRSA in the 
regions analyzed changed only slightly when we adjusted 
for confounders.
The adjusted OR for having MRSA was 1.5× higher 
among male participants (95% CI 1.2–2.0) than female par-
ticipants (Table 1). The crude risk differed slightly between 
age groups and was highest among persons 60–74 years of 
age (11 cases/1,000,000 travelers; 95% CI 8.1–13.8), but 
no difference was found in the OR between age groups in 
the adjusted model. Work-related travel showed a lower 
crude risk for being reported as having MRSA, but when 
adjusting for other risk factors, the OR of MRSA was 2.4× 
higher among persons who traveled for work purposes than 
in leisure travelers (95% CI 1.5–3.8). To examine to what 
degree inclusion or exclusion of carriers would change 
our ﬁ  ndings, analysis was repeated by using only the 133 
(49.8%) cases in travelers with MRSA disease. We found 
only minor changes in ranking of ORs for geographic re-
gions. The same 5 regions (Table 1) still ranked highest 
with higher ORs than other regions. The most prominent 
difference for ORs was that South America and Oceania 
and Paciﬁ  c Islands changed places in rank.
Percentages of CA-MRSA for the respective regions, 
correlated linearly with adjusted ORs (r = 0.81, p = 0.001). 
Among age groups, the proportion of cases of CA-MRSA 
was highest in persons 0–14 years of age (83.3%), lowest 
in persons 60–74 years of age (9.3%), and intermediate for 
other age groups.
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No. with MRSA 
infection (no. with 
MRSA disease) 
Crude risk/1 million 






  F  25,219,000 109 (62)  4.3 (3.6–5.2)  42.2 Reference
  M  20,634,000 158 (71)  7.7 (6.6–8.9)  27.2 1.5 (1.2–2.0) 
Age group, y 
  0–14  6,497,000 30 (24)  4.6 (3.2–6.6)  83.3 Reference
  15–29  8,657,000 72 (36)  8.3 (6.6–10)  31.9 1.0 (0.6–1.5) 
  30–44  13,234,000 49 (26)  3.7 (2.8–4.9)  44.9 0.8 (0.5–1.3) 
  45–59  12,342,000 62 (29)  5.0 (3.9–6.4)  22.6 0.8 (0.5–1.2) 
  60–74  5,127,000 54 (18)  11 (8.1–13.8)  9.3 1.2 (0.7–1.9) 
Purpose of travel 
  Leisure  36,323,000 237 (123)  6.5 (5.7–7.4)  34.2 Reference
  Work  9,532,000 30 (10)  3.1 (2.2–4.5)  26.7 2.4 (1.5–3.8) 
Region of origin† 
  Nordic  15,962,000 1 (0)  0.1 (0.01–0.4)  0.0 0.1 (0.01–0.6) 
  Western Europe  7,614,000 7 (3)  0.9 (0.4–1.9)  14.3 Reference
  Southern Europe  7,601,000 18 (5)  2.4 (1.5–3.8)  0.0 2.4 (1.0–5.8) 
  Central and Eastern Europe  2,885,000 7 (5)  2.4 (1.2–5.1)  28.6 2.8 (1.0–8.1) 
  UK and Ireland  2,815,000 26 (11)  9.2 (6.3–13.6)  7.7 10.3 (4.4–24..0) 
  North America  1,627,000 17 (4)  10.4 (6.5–16.8)  35.3 10.6 (4.2–26.7) 
  Northeastern Mediterranean  4,317,000 63 (30)  14.6 (11.4–18.7)  38.1 15.8 (7.0–35.6) 
  South America  152,000 6 (5)  39.5 (17.7–87.9)  33.3 31.2 (10.0–97.6) 
  East Asia  1,622,000 54 (27)  33.3 (25.5–43.5)  27.8 36.5 (16.2–82.0) 
  Oceania and Pacific Islands  250,000 11 (5)  44.0 (24.4–79.5)  36.4 43.0 (15.5–119.4) 
  Sub-Saharan Africa  232,000 11 (7)  47.4 (26.3–85.6)  54.5 46.3 (17.3–123.6) 
  North Africa and Middle East  774,000 46 (31)  59.4 (44.5–79.3)  58.7 59.0 (25.1–138.9) 
Total 45,855,000 267 (133)  5.8 (5.2–6.6)  33.3
*MRSA, methicillin-resistant Staphylococcus aureus; CI, confidence interval; OR, odds ratio. 
†Nordic: Denmark, Finland, Iceland, Norway; Western Europe: Austria, Belgium, France, Germany, Luxembourg, the Netherlands, Switzerland; Southern 
Europe: Italy, Malta, Monaco, Portugal, Spain; Central and Eastern Europe: Belarus, Bulgaria, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Poland, 
Romania, Russia, Slovakia, Czech Republic, Ukraine; North America: Canada, Cuba, Dominican Republic, Guadeloupe, Guatemala, Mexico, Panama, 
United States; Northeastern Mediterranean: Albania, Bosnia-Herzegovina, Cyprus, former Yugoslavia, Greece, Croatia, Macedonia, Serbia, Slovenia, 
Turkey; South America: Brazil, Chile, Colombia, Ecuador, Peru, Venezuela; East Asia: Afghanistan, Bangladesh, Cambodia, China, Hong Kong, India, 
Indonesia, Japan, South Korea, Malaysia, Maldives, Mongolia, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand, Vietnam, the Philippines; Oceania and 
Pacific islands: Australia, Hawaii, New Zealand, Samoa; Sub-Saharan Africa: Angola, Botswana, Chad, Ethiopia, the Gambia, Ghana, Kenya, Congo–
Kinshasa, Madagascar, Senegal, Sierra Leone–Togo, Somalia, Sudan, Swaziland, South Africa, Tanzania–Uganda; North Africa and Middle East: 
Algeria, Egypt, Iraq, Iran, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Saudi Arabia, Syria, Tunisia, United Arab Emirates.RESEARCH
MRSA in Immigrants
A total of 56 persons who had recently arrived in Swe-
den as immigrants had cases of MRSA (Table 2), giving an 
overall risk of 15.9 (95% CI 12.0– 20.7) cases/100,000 im-
migrants. MRSA disease was present in 27 (48.2%) of the 
immigrants. Twenty of the persons with MRSA came from 
the former Yugoslavia. The highest number of immigrants 
(n = 45,587) also came from this country; these persons had 
a risk of 43.8 (95% CI 26.8–67.8) MRSA cases/100,000 
immigrants. Nearly as many immigrants came from Iraq, 
but the risk for MRSA was lower for this group (9.1, 95% 
CI 2.5–23.4 cases/100,000 immigrants).
MRSA in Adopted Children
In 2000–2003, a total of 4,169 children were adopted 
from non-Nordic countries. Forty adopted children from 12 
countries were reported as having cases of MRSA shortly 
after their arrival in Sweden, i.e., 9.6 (95% CI 6.9–13.0) 
cases per 1,000 adoptions (Table 3). Of these adopted chil-
dren with MRSA, 6 had MRSA disease. Risk for having 
MRSA ranged from 3.0/1,000 adoptions of children from 
Vietnam (95% CI 0.1–16.8) to 74.1/1,000 adoptions of chil-
dren from the Philippines (95% CI 9.1–242.8). The largest 
number of adopted children (n = 1,074) came from the Peo-
ple’s Republic of China. However, only 6.5/1,000 adoptees 
(95% CI 2.6–13.4) from this country had MRSA. Children 
adopted from South Korea showed 30.0 cases/1,000 adop-
tions (95% CI 16.5–49.8).
Type of MRSA and Geographic Region of Acquisition
STs inferred from PFGE results and region of acquisi-
tion for 414 MRSA cases (excluding secondary cases and 
cases with STs seen in <5 cases) are shown in the online Ap-
pendix Table (www.cdc/gov/EID/content/16/2/189-appT.
htm). Also shown are the number of HA-MRSA and CA-
MRSA cases per ST and region of acquisition. HA ST22 
and ST36 predominated in cases from the United Kingdom 
and Ireland (15/33 and 11/33 MRSA cases, respectively). 
Among 92 cases from East Asia, the predominant MRSA 
were HA ST239 (n = 22 cases), CA ST30 (n = 13 cases), 
and CA ST72 (n = 6 cases). CA ST30 isolates were also 
seen in 5 cases from neighboring areas (3 from the Oceania 
and Paciﬁ  c Islands region and 2 from Hawaii that belonged 
to North American region). Among the 50 cases from North 
Africa and the Middle East, CA ST80 (n = 18 cases) domi-
nated. ST 80 was also isolated from 21 of 90 cases from the 
neighboring northeastern Mediterranean region. However, 
this region was mainly characterized by 30 HA ST239 (n = 
30 cases). In cases from southern Europe, HA ST228 was 
most frequently seen (11/36 cases). Overall, STs 5, 22, 36, 
125, 228, 239, and 241 were found most often in cases of 
HA-MRSA, and STs 30 and 80 were found most often in 
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Table 2. Imported cases of MRSA acquisition among immigrants, Sweden, 2000–2003* 
Country of origin  No. immigrants† 
No. with MRSA acquisition 
(no. with MRSA disease)  Risk/100,000 immigrants (95% CI) 
Malta 21 1 (0)  4,761.9 (120.5–23,816.0) 
Kazakhstan 933 4 (2)  428.7 (116.9–1,094.0) 
South Africa  556 2 (1)  359.7 (43.6–1,293.3) 
Sudan 360 1 (1)  277.8 (7.0–1,537.9) 
Italy  1,382 2 (1)  144.7 (17.5–521.8) 
Ecuador 995 1 (1)  100.5 (2.5–558.6) 
Lebanon 2,100 2 (0)  95.2 (11.5–343.6) 
Mongolia 1,055 1 (1)  94.8 (2.4–527.0) 
Japan 1,274 1 (0)  78.5 (2.0–436.6) 
The Philippines  1,335 1 (1)  74.9 (1.9–416.6) 
Afghanistan 6,166 4 (3)  64.9 (17.7–166.0) 
United States  4,094 2 (0)  48.9 (5.9–176.4) 
Former Yugoslavia  45,587 20 (10)  43.8 (26.8–67.8) 
Germany  6,564 2 (0)  30.5 (3.7–110.0) 
Poland 3,658 1 (0)  27.3 (0.7–152.2) 
Iran 7,856 2 (1)  25.5 (3.1–91.9) 
Thailand 4,883 1 (0)  20.5 (0.5–114.0) 
United Kingdom  5,306 1 (0)  18.9 (0.47.7–105.0) 
Turkey  5,568 1 (1)  18.0 (0.5–100.0) 
Russia 8,254 1 (0)  12.1 (0.3–67.5) 
Somalia 8,546 1 (1)  11.7 (0.3–65.2) 
Iraq 43,730 4 (3)  9.1 (2.5–23.4) 
Other countries  191,302 0 –
Total 351,525 56 (27)  15.9 (12.0–20.7) 
*MRSA, methicillin-resistant Staphylococcus aureus; CI, confidence interval. 
†Included in the immigration figures were persons who received a residence permit because of family ties, European Economic Area convention, and 
labor permits; visiting students; and asylum seekers per country of citizenship. Imported MRSA, Sweden
cases of CA-MRSA. Strains acquired in North America or 
European regions were associated with HA-MRSA.
Discussion
We have estimated risks for MRSA among travelers 
returning from speciﬁ  c geographic regions. Other studies 
have reported individual cases of MRSA diagnosed in con-
nection with travel (10,11,23–25). Kaiser et al. (12) studied 
patients in the Netherlands who were repatriated after hav-
ing received healthcare abroad, but found no association 
between country or region and MRSA diagnosis. However, 
the participation rate in their study was low, and the lack of 
statistically signiﬁ  cant results could have been caused by 
the low number of cases.
The overall prevalence and transmission rate of MRSA 
within a country or region is just one of several factors that 
can inﬂ  uence the risk for MRSA acquisition by travelers to 
that country or region. This risk will also depend on type of 
exposure and duration of stay. For example, risk for MRSA 
acquisition will vary, depending on whether the person had 
received healthcare or had only community contacts, wheth-
er he or she stayed in a hotel at a holiday resort for a week, 
stayed with relatives for 3 months, or just stayed overnight 
on a business trip. In Europe, we observed a relatively high 
risk for MRSA acquisition in travelers to the United King-
dom, Ireland, and southern Europe, which is consistent with 
the high prevalence of MRSA reported for these regions 
(26–28). Other studies have shown that MRSA is hyperen-
demic to the Paciﬁ  c region, East Asia, the Mediterranean 
region, and the Middle East (27–29). Thus, the higher risk 
for MRSA among travelers returning from these regions in 
our study may reﬂ  ect such hyperendemicity. In addition, we 
found a higher risk for MRSA among travelers to sub-Saha-
ran Africa and South America, and a risk for MRSA among 
travelers to central and eastern Europe that is comparable to 
that among travelers to southern Europe.
The risk for immigrants and adopted children of ac-
quiring MRSA may not be representative of the overall risk 
in the general population in their respective countries of 
origin. These 2 populations may have spent time in institu-
tional settings (e.g., orphanages, refugee camps, or hospi-
tals) in which the risk for MRSA exposure may be different 
from that in the community in general. In addition, analysis 
of MRSA risk among newly adopted children and immi-
grants was based on small numbers of persons, which re-
sulted in wide CIs of the estimated risks. Despite this uncer-
tainty, agreement was seen between the estimated risk for 
MRSA acquisition among returning travelers, immigrants, 
and adopted children. Eight of 12 countries from which the 
adopted children with MRSA originated and 14 of the 22 
countries from which immigrant cases originated belonged 
to the 6 regions with highest risk for MRSA among travel-
ers (northeastern Mediterranean, South America, East Asia, 
Oceania and Paciﬁ  c islands, sub-Saharan Africa, and North 
Africa and the Middle East).
Measuring the risk for MRSA in travelers, adopted 
children, and immigrants involved analyzing 3 different 
groups related to speciﬁ  ed countries and regions. Because 
of the large degree of agreement between the 3 groups, re-
sults obtained may reﬂ  ect not only risks for MRSA in these 
3 populations, but also an overall comparatively higher risk 
for MRSA in some regions than in others.
The study was based on persons (carriers and those 
with clinical disease) with reported cases of MRSA in Swe-
den during 2000–2003. Only minor changes, which did not 
affect our primary ﬁ  ndings, were seen when carrier cases 
were excluded from the travel analysis. Approximately 
50% of MRSA cases among immigrants, but only 15% 
(6/40) of adopted children, had MRSA disease. Twelve 
of the 13 countries from which immigrants originated be-
longed to the 6 regions with highest risk for MRSA among 
travelers. For adopted children, the numbers of countries 
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Table 3. Imported cases of MRSA acquisition among children adopted from other countries, Sweden, 2000–2003* 
Country No. adoptions
No. with MRSA acquisition  
(no. with MRSA disease)  Risk/1,000 adoptions (95% CI) 
The Philippines  27 2 (0)  74.1 (9.1–242.8) 
South Korea  467 14 (0)  30.0 (16.5–49.8) 
Bulgaria 91 2 (1)  22.0 (2.7–77.1) 
Belarus 174 3 (1)  17.2 (3.6–49.6) 
Russia 263 4 (0)  15.2 (4.2–38.5) 
Ethiopia 71 1 (1)  14.1 (0.4–76.0) 
Ukraine 74 1 (0)  13.5 (0.3–73.0) 
People’s Republic of China  1,074 7 (3)  6.5 (2.6–13.4) 
Colombia 460 3 (0)  6.5 (1.3–18.9) 
South Africa  154 1 (0)  6.5 (0.16–35.6) 
India 243 1 (0)  4.1 (0.1–22.7) 
Vietnam 328 1 (0)  3.0 (0.1–16.8) 
Other countries  743 0 –
Total 4,169 40 (6)  9.6 (6.9–13.0) 
*MRSA, methicillin-resistant Staphylococcus aureus; CI, confidence interval. RESEARCH
involved and cases decreased when carriers were excluded. 
However, 2 of 4 countries (4 of 6 cases) still belonged to 
the same 6 regions. Results for these 3 populations with 
acquired MRSA are consistent even when carriers were ex-
cluded from the analysis.
One strength of our study is that all regions/countries 
were investigated by using the same surveillance system, 
thus avoiding problems that might arise when data for dif-
ferent countries are compiled from different sources. Be-
cause the travel analysis was based on residents of Sweden 
who traveled to other countries and results were adjusted 
for sex and age, the main conclusions should also be val-
id for other western countries. Possible biases related to 
MRSA cases reported in Sweden during 2000–2003 and 
use of the TDB have been evaluated (16,30). Information 
from the TDB has shown good agreement with data from 
other sources (31). We could not control for length of stay 
of travelers at their destination because such information 
for MRSA cases was not available. However, persons with 
cases of MRSA who traveled for work purposes were com-
monly employed at the destination for a few months, rather 
than having been on short business trips.
Most persons infected with MRSA had HA-MRSA; 
only 33% had CA-MRSA. However, CA-MRSA showed a 
strong correlation with regions with a high risk for MRSA 
among travelers. This ﬁ  nding might be caused by a higher 
propensity among clinicians to sample patients with a his-
tory of activity (e.g., backpacking) under less than optimal 
sanitary conditions or travel to exotic regions. The 5 re-
gions with the highest OR of acquiring MRSA in adjusted 
analysis were outside Europe.
Geographic distribution of MRSA STs was consistent 
with that in studies of other regions. ST22 and ST36 are 
well documented in the healthcare system in the United 
Kingdom (32). ST80 is common in the Mediterranean and 
Balkan region, the Middle East, and several countries in Eu-
rope, and epidemiologically related to persons with direct 
or indirect contact with the Mediterranean and Middle East 
(1,11,12,23–25). ST239 is common Asia (33,34) and the 
northeastern Mediterranean (35); ST30 is common in the 
Paciﬁ  c region, East Asia, and Oceania (1,36); and ST228 is 
common in southern Europe and Germany (37,38).
In addition to showing an association between speciﬁ  c 
STs and regions, we also identiﬁ  ed the transmission set-
ting (healthcare or community) in which the isolate was 
acquired. We observed that most STs among imported 
cases of MRSA were associated with either HA-MRSA 
or CA-MRSA. ST30 and ST80 were strongly associated 
with CA-MRSA. ST72 was identiﬁ  ed only among 8 ad-
opted children from South Korea. However, information 
for the orphanages was not available. Thus, the possibility 
that 8 children could have been part of the same local trans-
mission chain could not be ruled out. However, ST72 has 
recently been reported from several areas of South Korea 
among children and as a community-associated sequence 
type (39,40).
Several limitations of our study involve factors rel-
evant to MRSA acquisition (length of stay abroad, contacts 
with institutions with a higher probability of MRSA trans-
mission such as healthcare settings, orphanages, or refu-
gee camps) that were not measured. In addition, there may 
have been inconsistencies in how MRSA cases were se-
lected in the surveillance system. In some counties in Swe-
den, MRSA screening of adopted children is conducted; 
in other counties, it is not practiced. Thus, underdiagnosis 
of MRSA carriage among adopted children was likely. No 
similar screening recommendations are known for newly 
arrived refugees or immigrants.
In countries with a low prevalence of MRSA, a larger 
proportion of cases are imported than in countries with a 
high prevalence of MRSA. The risk for additional domestic 
transmission indicates a greater need to focus public health 
measures toward these imported cases. We observed dif-
ferences in risk for MRSA among travelers returning from 
different regions, adopted children, and immigrants. Risk 
estimates for MRSA measured in these 3 groups showed 
a consistent pattern; some regions showed a higher risk 
for acquiring MRSA. Although most imported cases of 
MRSA were HA-MRSA, community acquisition showed 
a correlation with regions that have a high risk for MRSA 
among travelers. Knowledge of these differences in risk for 
MRSA will improve control measures and decrease domes-
tic transmission.
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